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dvances in DNA sequencing technology have
provided researchers with the exciting opportunity to
examine microbial diversity at different sites on the
human body without having to rely on cumbersome and
oftentimes inadequate culture-based methods.
1 Our guts
contain tens of trillions of microbes, by far the largest
collection among our various body habitats. The gut
ecosystem is dominated by members of one of three
domains of life on earth, Bacteria, although members of
the other two known domains, Archaea and Eukarya,
are also represented, as are their viruses. Culture-inde-
pendent (“metagenomic”) studies have shown that (i)
early colonization of the body is affected by the mode of
delivery
2; (ii) assembly of the gut microbial community
occurs over the course of the first 3 years of life
3; (iii)
there is pronounced interpersonal variation in the bac-
terial species composition of a given body habitat
1,4; (iv)
within an individual microbial community structure
varies considerably between body habitats
1; and (v) feces
provide an excellent, safely obtained representative sam-
ple for defining interpersonal differences in gut com-
munity ecology.
5
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Our understanding of the vast collection of microbes that
live on and inside us (microbiota) and their collective genes
(microbiome) has been revolutionized by culture-inde-
pendent “metagenomic” techniques and DNA sequencing
technologies. Most of our microbes live in our gut, where
they function as a metabolic organ and provide attributes
not encoded in our human genome. Metagenomic studies
are revealing shared and distinctive features of microbial
communities inhabiting different humans. A central ques-
tion in psychiatry is the relative role of genes and environ-
ment in shaping behavior. The human microbiome serves
as the interface between our genes and our history of envi-
ronmental exposures; explorations of our microbiomes
thus offer the possibility of providing new insights into our
neurodevelopment and our behavioral phenotypes by
affecting complex processes such as inter- and intra per-
sonal variations in cognition, personality, mood, sleep, and
eating behavior, and perhaps even a variety of neuropsy-
chiatric diseases ranging from affective disorders to autism.
Better understanding of microbiome-encoded pathways
for xenobiotic metabolism also has important implications
for improving the efficacy of pharmacologic interventions
with neuromodulatory agents.  
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the relative effects of genotype and environment in
shaping the structures of our microbial communities.
Remarkably, the overall degree of similarity of gut bac-
terial community composition is the same in adult
mono- and dizygotic twin pairs.
6 Moreover, members of
the same family share a greater degree of similarity in
their gut bacterial community configurations than do
those belonging to different families.
6 Each individual
contains a distinct collection of gut bacterial species,
even if they are a member of a monozygotic twin pair.
6,7
While there does not appear to be a core set of abundant
bacterial species in a given body habitat that is shared
among all humans,
7,8 there is a shared set of microbial
genes, at least in the gut.
6 Families not only share this
core microbiome but also have a greater degree of over-
all similarity in the variable component when compared
with unrelated individuals.
6
Together, these findings reveal a flow of microbes and
microbial genes that occur between members of a fam-
ily and across generations within a kinship. This flow
appears to be influenced by early environmental expo-
sures, as evidenced by the lack of a significant difference
in the overall degree of phylogenetic similarity of gut
communities among mono- compared with dizygotic
twin pairs. Early environmental exposures include phys-
ical contact among family members, but also exposure
to various diets, including mother’s milk. As such, it is
reasonable to conclude that features of our human post-
natal development, including central nervous system
(CNS) functions, are influenced by factors that also
impact the assembly and operations of our microbial
communities. The fact that intrapersonal variation in
microbial community composition within a body habitat
is substantially less than interpersonal variation means
that each individual represents his or her own best con-
trol for assessing the effects of various disturbances/per-
turbations (eg, dietary, pharmacologic) on micro-
biota/microbiome structure and function, while family
provides the “next best” reference controls. One of the
striking features of a variety of neuropsychiatric diseases
(eg, affective disorders) is their variance, with differences
observed across individuals in terms of their suscepti-
bility, in the combination of systems that are disturbed,
and in the therapeutic and adverse responses to various
medications. This article underscores the possibility that
the microbiome represents a source of this observed
variance.
Microbial communities that affect behavior
The literature is replete with descriptions of the effects of
infection with a variety of eukaryotic, bacterial, and viral
species on host behavior. An effect with a well-understood
evolutionary basis is the interaction between Toxoplasma
gondii—the eukaryotic pathogen that causes toxoplas-
mosis—and its rodent host. T. gondii, like many parasites,
has a complex lifestyle that is partly completed in one host
(rodent) and then in another host (feline); the rodent host
loses its innate fear of the smell of bobcat urine, and thus
seeks out locations with that smell,
9,10 increasing its
chances of being consumed and transmitted to the other
host. T. gondii has also been linked to behavioral effects
in nontarget hosts, including humans, where gender-spe-
cific effects on personality traits including self-control,
warmth, and novelty seeking (eg, tendency towards high-
risk activities) have been observed.
11-13 Many viruses affect
behavior; for example, bornavirus (has been related to
mania and schizoaffective disorders
14-16); human immun-
odeficiency virus (linked to cognitive impairment, affec-
tive disorders, and psychosis
17-19), rabies (a zoonotic infec-
tion caused by an enveloped single-stranded RNA virus
that in its fulminant form is associated with hydropho-
bia
20). The same is true of bacteria; cognitive and emo-
tional disturbances have been associated with Brucella
suis infection
21; manic and psychotic symptoms resistant
to antipsychotics but treatable with antibiotics during
infection with Leptospira
22; baseline depression and anx-
iety caused by Mycobacterium tuberculosis
23; and obses-
sive-compulsive disorder (OCD) and pediatric autoim-
mune neuropsychiatric disorders associated with
streptococcal infections (PANDAS).
24,25
Poorly understood from a mechanistic perspective, but
perhaps more intriguing, are cases where an entire
microbial community impacts host behavior. These
effects have been noted when comparing the phenotypes
of mice reared from birth and from generation to gen-
eration under sterile conditions in specialized gnotobi-
otic isolators that prevent any exposure to environmen-
tal microbes (“germ-free” animals) with mice that have
been reared in the presence of microbes but under spec-
ified pathogen-free conditions (“conventionally raised”
animals), or mice that were reared germ-free and then
colonized at a given point in postnatal or adult life with
a microbiota transplanted from a conventionally raised
donor (so called “conventionalized” animals). For exam-
ple, germ-free mice exhibit basal behaviors in the ele-
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anxiety levels.
26 Using an implantable detector of loco-
motion for quantitative phenotyping, Backhed et al
27
found that germ-free wild-type (C57Bl/6J) mice have
significantly increased movement compared with their
microbe-laden counterparts, whether on a standard plant
polysaccharide-rich, low-fat chow diet or a diet high in
simple sugars and fat (Western diet). Conventionally-
raised genetically engineered mice lacking Toll-like
Receptor 5 (TLR5), a component of the innate immune
system that recognizes bacterial flagellin, have an altered
gut microbiota, eat substantially more than their con-
ventionally-raised wild-type counterparts, and become
obese. The same phenotype can be transmitted to germ-
free wild-type mice by transplanting a gut microbiota
from a conventionally-raised TLR5 knockout donor,
28
suggesting that it is the induced change in the microbiota
that is changing the eating behavior. Fascinatingly, these
mice also develop metabolic syndrome, which is a fre-
quent complication of the use of certain psychotropic
drugs. It is outside the scope of this review to cover the
extensive literature relating certain psychotropic drugs
to the development of obesity and metabolic syndrome.
However, data from models such as the TLR5 knockout
mice indicate that there can be links between the micro-
biota and metabolic syndrome,
28 and we know that the
microbiota can have large effects on the metabolism of
certain drugs.
29Therefore it is tempting to speculate that
the microbiota should be considered as a possible factor
influencing metabolic syndrome in response to psy-
chotropic drugs in a subset of patients. In mice, micro-
bial communities also appear to be instrumental in gen-
erating scents (skin odor) and affect mate
preferences.
30,31This link between odor and mate prefer-
ence has also been suggested, but not established in
humans,
32 although the connection between bacteria and
mate choice has been established in fruit flies
33 and may
therefore be widespread. 
Diet, behavior, and the gut microbiota
There are numerous reports of diet affecting various man-
ifestations of psychiatric disorders, including schizophrenia,
mono- and bipolar depression,
34 attention deficit –hyper-
activity disorder (ADHD),
35,36 and autism,
37,38 although the
underlying mechanisms are obscure and not all studies are
adequately controlled. Diet has also been shown to play a
key role in shaping the structure and functional properties
of the gut microbiota in both humans
5,34 and in mice.
29,39-43 In
considering the underlying mechanisms for how diet affects
behavior, the microbiota cannot be overlooked, because
associations between diet and psychiatric disorders are
often thought to be related to metabolites of dietary com-
ponents.
35,44,45The enzymes that produced these metabolites
may be encoded in our human genome, or in the genomes
of the microbes that inhabit our gut. The surprisingly high
compositional variation in gut bacteria across individuals
6
stands in stark contrast to the surprisingly small amount of
genetic diversity uncovered in the sequencing of our
human genomes. Differences in our microbial communi-
ties may thus be one of the most important factors in dif-
ferences in the metabolites that individuals extract from
determining the differences in the metabolites that differ-
ent individuals may extract from similar diets.
Is the gut microbiome involved in autistic
spectrum disorders?
DSM-IV (and ICD-10) classifies a number of disorders
under the broad category pervasive developmental dis-
order (PDD) or Autistic Spectrum Disorders (ASD)
and include: autism or autistic disorder (OMIM
209850), Asperger syndrome (AS), Rett syndrome
(RTT; OMIM 312750), childhood disintegrative disor-
der (CDD), and pervasive developmental disorder-not
otherwise specified (PDD-NOS).
46 The prevalence of
the broader ASD phenotype can approach ~0.5% in
some populations.
36 Depending upon the phenotyping
method used and disease severity, symptoms can be
detected in very early childhood.
47 Host genetic factors
appear to play a key role, with a large British study
reporting a significantly higher concordance rate of cer-
tain phenotypic characteristics among monozygotic
compared with dizygotic twins (60% to 92% versus 
0% to 10%).
48 Genome-wide association studies have
revealed a number of loci strongly associated with
ASDs, including those involved in synaptogenesis and
synaptic function (eg, neurexins and the neuroligins that
bind them
49,50). 
Although heritability in the British twin study was cal-
culated to be >90%, environmental influences may be
still considerable. A “gut-brain” linkage for ASDs has
been proposed, based in part on reports that children
with ASDs often experience a range of gastrointestinal
disorders. 
51,52 A few reports indicate that children with
ASDs have a greater representation of members of the
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51-53 in their fecal microbiota,
although as noted below, comprehensive analyses of gut
microbial ecology in affected and reference control pop-
ulations have not yet appeared in the literature.
Microbial metabolism may have an impact on disease
pathogenesis in ASD. Initial evidence for this came from
a small study of autistic children treated with the mini-
mally absorbed glycopeptide antibiotic vancomycin;
short-term improvement was reported,
54 leading to the
suggestion that autistic symptoms may be related to the
production of neurotoxic metabolites by the gut micro-
biota. Two subsequent studies of metabolites in urine
have supported that microbial metabolism results in
altered metabolite profiles in children with ASD. The
application of pattern recognition analysis to compare
1H-NMR spectra from the urine of children with ASD to
their relatives and age-matched controls indicated that
among the metabolites that changed in concentration
with autism were mammalian-microbial cometabolites,
including dimethylamine, hippurate, and phenyacetyl-
glutamine.
45Another study showed that urinary levels of
3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA)
are higher in children with autism compared with neu-
rotypical controls.
44 One potential source of this com-
pound is the conversion of phenylalanine from the diet
to m-tyrosine and then to 3-hydroxyphenyl-propionic
acid by microbial enzymes, followed by conversion to
HPHPA by human enzymes.
44 m-Tyrosine induces a
characteristic behavioral symptom in rats that includes
stereotypical behavior, hyperactivity, and hyper-reactiv-
ity,
55 indicating that this compound may be specifically
contributing towards autistic behaviors. A microbial ori-
gin for HPHPA is supported by its decrease in urine
after patients were treated for Clostridial infections with
metronidazole, an antibacterial agent with specificity
toward anaerobic bacteria.
44 Some species within the
Clostridiales are known to produce phenylpropionic acid
and/or monohydroxyphenylpropionic acid, which are
very closely related biochemically to m-tyrosine and
HPHPA.
44
A link between autism, gastrointestinal problems, and
gut microbiota suggests that diet has the potential to
impact symptoms, and parents of autistic children have
long been exploring the impact of dietary and micro-
biota manipulations on behavior, for instance commonly
using gluten-free and/or casein-free (GF/CF) diets, pro-
biotics, and nutritional supplements. Two randomized
controlled trials of the GF/CF diet indicated that it may
improve symptoms in some children,
37,38 although these
trials were small, both in terms of size and duration.
Although the GF/CF diet may improve symptoms by
inducing changes in the microbiota and/or their metabo-
lites, another mechanism is by increasing gut integrity.
Abnormally high intestinal permeability (IPT), or a
“leaky gut,” has also been associated with autism, sug-
gesting that autistic individuals may have increased sen-
sitivity to components of our diet and their metabolites,
because they can more easily access the bloodstream.
56
Autistic individuals on a GF/CF diet had significantly
lower intestinal permeability compared with individuals
on an unrestricted diet.
56 Genetic factors have also been
implicated in impaired gut integrity in autistic individ-
uals; a mutation affecting the expression of the gene
encoding the MET receptor tyrosine kinase has been
associated with both ASD and gastrointestinal condi-
tions, and functions in both brain development and gas-
trointestinal repair.
57 To our knowledge no study has
evaluated how the GF/CF diet affects the structure, gene
expression, and function of the gut (fecal) microbiota or
microbiome. 
In general, studies of the gut microbiota in children with
ASDs have been very limited, typically examining just a
few subjects, with shallow sequencing of bacterial 16S
rRNA gene amplicons generated from just a few
biospecimens/participant (ie, extensive time series stud-
ies have not been performed), and without concomitant
analyses of (i) microbiome gene content (by shotgun
sequencing of total fecal community DNA); (ii) micro-
biome gene expression (by RNA-Seq profiling of the
community’s meta-transcriptome); or (iii) microbial
metabolism (or host-microbial cometabolism, eg, by MS
or NMR). Several groups are currently conducting these
types of analyses. The results may identify micro-
biota/microbiome biomarkers useful for improved clas-
sification schemes, for understanding pathophysiology,
and for monitoring the efficacy of therapeutic interven-
tions. With improved phenotyping (eg, using functional
magnetic resonance imaging [fMRI] or monitoring eye-
tracking) earlier diagnosis may be possible, allowing for
prospective characterizations of microbial community
metabolism and host-microbial cometabolism during
postnatal development (and in the mother). This empha-
sis on the potential importance of microbial metabolism
is based in part on the hypothesis that neuroactive com-
pounds produced by the gut microbiota may play an
important role in shaping synaptogenesis and synaptic
Translational research
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als with genetic mutations affecting synaptic components
or neurotransmitters that operate at various types of
synapses. 
The gut microbiome and therapeutics
The gut microbiota has the capacity to process xenobi-
otics (compounds foreign to a living organism), includ-
ing over 30 known drugs administered to humans,
58-61
through a variety of biotransformations including reduc-
tion, dehydroxylation, acetylation/deacetylation, prote-
olysis, denitration, and hydrolysis.
60
One avenue for exploring the inter-relationships
between orally administered xenobiotics, the human gut
microbiome, and host metabolism is to use gnotobiotic
animals colonized with defined consortia of microbes
from human or animal donors.
62A notable example was
the use of rats that were either germ-free or colonized
with a human fecal microbiota to investigate the micro-
bial production of equol, a metabolite with a proposed
protective effect against cancer, from a soy-isoflavone
containing diet.
63 Humans vary in their ability to produce
equol from daidzein (a soy-isoflavone). This metabolic
phenotype is transmissible via the microbiota, where
germ-free rats colonized with a fecal sample from a high
equol-producing human donor excreted significant
amounts of equol, while gnotobiotic rats colonized with
a fecal sample from a low equol-producing donor had no
detectable equol in their urine.
63
In addition to directly impacting the metabolism of
xenobiotics, the gut microbiota can also modify inactive
drugs that have been conjugated and secreted in the bile.
These reactions rely on bacterial glucuronidases and sul-
fatases that have evolved to hydrolyze bile acids conju-
gated to glycine or taurine.
64 The resulting bacterial
deconjugation allows the products to be reabsorbed. In
some cases, this mechanism results in an extension of the
half-life of certain drugs, including estrogens,
65 digitoxin,
60
indomethacin,
66 and even morphine.
60
These observations raise the possibility of blocking micro-
bial deconjugation through combination therapy, to avoid
recirculation. As an illustration of this concept, Wallace et
al
67 focused on CPT-11 (irinotecan), a chemotherapeutic
drug currently in clinical use that has a dose-limiting side
effect of severe diarrhea. The administered compound is
a prodrug that is processed in vivo to yield the active
metabolite SN-38.
68 SN-38 is then glucuronidated in the
liver by uridine diphosphate (UDP)-glurunosyltransferase
to form SN-38G,
69 which is secreted through the bile into
the small intestine. As with other compounds, this inactive
form is then reactivated by bacterial β-glucuronidases,
70
contributing to the development of delayed-onset diar-
rhea in 40% of treated patients.
71,72
One approach to limit this bacterial metabolism would
be to use broad-spectrum antibiotics.
71 However, recent
metagenomic studies have highlighted the long-term
effects that antibiotic treatment can have on the com-
mensal microbiota,
73,74 potentially interfering with host-
microbial interactions that contribute to maintaining
health or preventing disease. Alternatively, if the bacte-
rial enzymes of interest are known, as is the case for
irinotecan deconjugation, these enzymes can be tar-
geted. To achieve this goal, E. coli β-glucuronidase was
purified, its X ray structure determined,
67 and used as the
target or a chemical screen that yielded an inhibitor of
the bacterial (but not mammalian) enzyme. The lead
compound was not bactericidal for several members of
the human gut microbiota in vitro, nor was it toxic to
mammalian cells. Moreover, surveys of groups of mice
treated with CPT-11 alone, or with the enzymatic
inhibitor alone, or with both the inhibitor and CPT-11,
revealed that combination therapy greatly reduced
symptoms.
67
These findings suggest that the gut microbiota is likely an
important mediator of the bioavailability and toxicity of
some drugs. How much of the interpersonal variation in
pharmacokinetics is due to the microbial versus human
component of our metagenomes? Does diet impact drug
metabolism via the gut microbiota? As in the case of
irinotecan, can combination therapies be developed that
block or promote key microbial transformations?  Can dif-
ferences in the metabolism of orally administered drugs
be used as biomarkers for differences in gut microbial
metabolism that are relevant to the pathogenesis of neu-
ropsychiatric disorders? Although current lists of orally
administered drugs known to be subject to microbial mod-
ification is small, it seems prudent to explore this avenue
when considering psycho/neuroactive drugs that have nar-
row therapeutic indices, or various idiosyncratic effects.
Conclusions
Our microbial communities both reflect and help define
the interactions between our human genotypes and our
myriad environmental exposures. In the quest to under-
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the many facets of normal human behavior, the varia-
tions in behavior that occur as we age, and the pertur-
bations in our behavior associated with various forms
of mental disorders classified according to currently
used phenotypic/diagnostic parameters, it seems timely
to incorporate studies of our microbiomes. The chal-
lenge ahead is in large part “cultural.” Groups of clini-
cian-scientists with deep understanding of higher brain
function, including how to quantitatively phenotype
these functions, must unite with those who study micro-
bial ecology, familiarize each other with their respective
conceptual, experimental and computational tools, and
then coevolve plans for well-controlled clinical studies.
This effort requires crossing traditional disciplinary
boundaries and surmounting formidable language bar-
riers. Moreover, since varying cultural traditions
(lifestyles) play an enormous role in shaping features of
human behavior and our microbial ecology, the “cul-
tural” context in which these human studies are per-
formed must be carefully defined. Nonetheless, the
stage for these interdisciplinary initiatives is in many
ways already set. For example, the National Institute of
Health (NIH)’s Human Connectome Project is waiting
to be “connected” to the NIH’s Human Microbiome
Project. ❏
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El continuo mente-cuerpo-microorganismos
Nuestro conocimiento acerca de la amplia variedad
de microbios que viven dentro y fuera de nosotros
(microbiota) y de sus genes colectivos (microbioma)
ha sido revolucionado por técnicas “metagenómicas”
independientes de cultivos y por las tecnologías para
secuenciar el ADN. La mayoría de nuestros microbios
viven en nuestro intestino, donde ellos funcionan
como un órgano metabólico y confieren atributos
que no están codificados en nuestro genoma
humano. Los estudios metagenómicos están reve-
lando características compartidas y distintivas de las
comunidades microbianas que habitan en los dife-
rentes hombres. Una pregunta central en psiquiatría
es el papel relativo de los genes y del ambiente en la
formación de la conducta. El microbioma humano
sirve como la interfaz entre nuestros genes y nuestra
historia de exposiciones al ambiente; por lo que las
exploraciones de los microbiomas ofrecen una nueva
aproximación al neurodesarrollo y a los fenotipos
conductuales al influir en complejos procesos como
las variaciones inter e intra personales en la cognición,
la personalidad, el ánimo, el sueño y la conducta ali-
mentaria, e incluso en una variedad de enfermeda-
des neuropsiquiátricas que van desde los trastornos
afectivos al autismo. Una mejor comprensión de las
vías codificadas por el microbioma para el metabo-
lismo xenobiótico también tiene importantes impli-
caciones para mejorar la eficacia de las intervencio-
nes farmacológicas con agentes neuromoduladores. 
Le continuum pensée-corps-microbe
Notre compréhension de la grande variété de
microbes vivant sur et à l'intérieur de notre corps
(microbiotie) ainsi que de leurs gènes (microbiome)
a été révolutionnée par des techniques indépen-
dantes des cultures dites « métagénomiques » et les
technologies de séquençage de l’ADN . La plupart
de nos microbes vivent dans notre intestin où ils
fonctionnent comme un organe métabolique pré-
sentant des caractéristiques non codées dans notre
génome humain. Des études métagénomiques ont
montré des caractéristiques partagées et distinctives
des colonies microbiennes habitant chez différents
êtres humains. Le rôle relatif des gènes et de l’en-
vironnement dans l’élaboration du comportement
est une question centrale en psychiatrie. Le micro-
biome humain est une interface entre nos gènes et
nos antécédents d’exposition à un environnement ;
l’analyse de nos microbiomes nous offre donc la
possibilité de regarder autrement notre neurodé-
veloppement, nos phénotypes comportementaux
en influant sur des processus complexes comme la
connaissance, la personnalité, l’humeur, le sommeil
et l’alimentation et peut-être même sur des mala-
dies psychiatriques allant des troubles affectifs à
l’autisme. Une meilleure compréhension des voies
codées par le microbiome pour le métabolisme
xénobiotique est importante pour améliorer l’effi-
cacité des traitements pharmacologiques par neu-
romodulateurs.
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